[1]

National Comprehensive Cancer Network. NCCN clinical practice guidelines in ovarian cancer including fallopian tube cancer and primary peritoneal cancer. version 3,2024[EB/OL].(2024-07-15)[2024-11-20] https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1453. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1453 本文引用 [1]

[2]

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in genetic/familial high-risk assessment: breast,ovarian,and pancreatic. version 1,2025[EB/OL].(2024-09-11)[2024-11-20] https://www.logan.org/wp-content/uploads/2024/09/genetics_bop.pdf. https://www.logan.org/wp-content/uploads/2024/09/genetics_bop.pdf 本文引用 [6]

[3]

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in genetic/familial high-risk assessment: Colorectal. version 1,2023[EB/OL].(2023-05-30)[2024-11-20] https://aim.clinic/wp-content/uploads/2023/09/genetic-familial-high-risk-assessment-colorectal.pdf. https://aim.clinic/wp-content/uploads/2023/09/genetic-familial-high-risk-assessment-colorectal.pdf 本文引用 [5]

[4]	The American College of Obstetricians and Gynecologist. Committee Opinion No. 176:The role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer in women at average risk[J]. Obstet Gynecol, 2017, 130(3):e146-e149. DOI:10.1097/AOG.0000000000002299. 本文引用 [1]

[5]	The American College of Obstetricians and Gynecologist. Hereditary cancer syndromes and risk assessment:ACOG Committee Opinion, Number 793[J]. Obstet Gynecol, 2019, 134(6):e143-e149. DOI:10.1097/AOG.0000000000003562. 本文引用 [2]

[6]	US Preventive Services Task Force, Grossman DC, Curry SJ, et al. Screening for ovarian cancer:US Preventive Services Task Force recommendation statement[J]. JAMA, 2018, 319(6):588-594. DOI:10.1001/jama.2017.21926. 本文引用 [1]

[7]	Sessa C, Balmaña J, Bober SL, et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes:ESMO Clinical Practice Guideline[J]. Ann Oncol, 2023, 34(1):33-47. DOI:10.1016/j.annonc.2022.10.004. 本文引用 [1]

[8]	Fotopoulou C, Hall M, Cruickshank D, et al. British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines:recommendations for practice[J]. Eur J Obstet Gynecol Reprod Biol, 2017, 213:123-139. DOI:10.1016/j.ejogrb.2017.04.016. 本文引用 [1]

[9]

Cancer Australia. Testing for ovarian cancer in asymptomatic women[EB/OL].(2019-02-01)[2024-11-20]https://www.canceraustralia.gov.au/publications-and-resources/position-statements/testing-ovarian-cancer-asymptomatic-women. https://www.canceraustralia.gov.au/publications-and-resources/position-statements/testing-ovarian-cancer-asymptomatic-women 本文引用 [1]

[10]

Chen L, Berek JS. Epithelial carcinoma of the ovary,fallopian tube,and peritoneum: Incidence and risk factors[EB/OL].(2024-09-06)[2024-11-20] https://www.uptodate.com/contents/epithelial-carcinoma-of-the-ovary-fallopian-tube-and-peritoneum-incidence-and-risk-factors. https://www.uptodate.com/contents/epithelial-carcinoma-of-the-ovary-fallopian-tube-and-peritoneum-incidence-and-risk-factors 本文引用 [1]

[11]	Eccles DM, Balmaña J, Clune J, et al. Selecting patients with ovarian cancer for germline BRCA mutation testing:findings from guidelines and a systematic literature review[J]. Adv Ther, 2016, 33(2):129-150. DOI:10.1007/s12325-016-0281-1. 本文引用 [1]

[12]	Wen H, Xu Q, Sheng X, et al. Prevalence and landscape of pathogenic or likely pathogenic germline variants and their association with somatic phenotype in unselected Chinese patients with gynecologic cancers[J]. JAMA Netw Open, 2023, 6(7):e2326437. DOI:10.1001/jamanetworkopen.2023.26437. 本文引用 [2]

[13]	Wu X, Wu L, Kong B, et al. The first nationwide multicenter prevalence study of germline BRCA1 and BRCA2 mutations in Chinese ovarian cancer patients[J]. Int J Gynecol Cancer, 2017, 27(8):1650-1657. DOI:10.1097/IGC.0000000000001065. 本文引用 [2]

[14]	Carlson KJ. Patient education: Screening for ovarian cancer[EB/OL].(2024-02-28)[2024-11-20]https://www.uptodate.com/contents/screening-for-ovarian-cancer-beyond-the-basics. https://www.uptodate.com/contents/screening-for-ovarian-cancer-beyond-the-basics 本文引用 [1]

[15]	Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality:the Prostate,Lung,Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial[J]. JAMA, 2011, 305(22):2295-2303. DOI:10.1001/jama.2011.766. 本文引用 [3]

[16]	Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer[J]. N Engl J Med, 2009, 361(2):170-177. DOI:10.1056/NEJMcp0901926. 本文引用 [1]

[17]

Menon U, Gentry-Maharaj A, Burnell M, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS):a randomised controlled trial[J]. Lancet, 2021, 397(10290):2182-2193. DOI:10.1016/S0140-6736(21)00731-5. 本文引用 [7]

[18]	US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Screening for gynecologic conditions with pelvic examination:US Preventive Services Task Force recommendation statement[J]. JAMA, 2017, 317(9):947-953. DOI:10.1001/jama.2017.0807. 本文引用 [1]

[19]	Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index possibilities for earlier detection[J]. Cancer, 2007, 109(2):221-227. DOI:10.1002/cncr.22371. 本文引用 [1]

[20]	Rossing MA, Wicklund KG, Cushing-Haugen KL, et al. Predictive value of symptoms for early detection of ovarian cancer[J]. J Natl Cancer Inst, 2010, 102(4):222-229. DOI:10.1093/jnci/djp500. 本文引用 [1]

[21]

Skates SJ, Greene MH, Buys SS, et al. Early detection of ovarian cancer using the risk of ovarian cancer algorithm with frequent CA125 testing in women at increased familial risk-combined results from two screening trials[J]. Clin Cancer Res, 2017, 23(14):3628-3637. DOI:10.1158/1078-0432.CCR-15-2750. 本文引用 [1]

[22]	Lu KH, Skates S, Hernandez MA, et al. Two stage ovarian cancer screening strategy using the risk of ovarian cancer algorithm (ROCA) identifies early stage incident cancers and demonstrates high positive predictive value[J]. Cancer, 2013, 119(19):3454-3461. DOI: 10.1002/cncr.28183. 本文引用 [2]

[23]	Han CY, Lu KH, Corrigan G, et al. Normal risk ovarian screening study:21-year update[J]. J Clin Oncol, 2024, 42(10):1102-1109. DOI:10.1200/JCO.23.00141. 本文引用 [2]

[24]	Anderson GL, McIntosh M, Wu L, et al. Assessing lead time of selected ovarian cancer biomarkers:a nested case-control study[J]. J Natl Cancer Inst, 2010, 102(1):26-38. DOI:10.1093/jnci/djp438. 本文引用 [1]

[25]	Cramer DW, Bast RC Jr, Berg CD, et al. Ovarian cancer biomarker performance in prostate,lung,colorectal,and ovarian cancer screening trial specimens[J]. Cancer Prev Res, 2011, 4(3):365-374. DOI:10.1158/1940-6207.CAPR-10-0195. 本文引用 [1]

[26]	Schorge JO, Modesitt SC, Coleman RL, et al. SGO white paper on ovarian cancer:etiology,screening and surveillance[J]. Gynecol Oncol, 2010, 119(1):7-17. DOI:10.1016/j.ygyno.2010.06.003. 本文引用 [1]

[27]	Coleman RL, Herzog TJ, Chan DW, et al. Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses[J]. Am J Obstet Gynecol, 2016, 215(1):82.e1-82.e11. DOI:10.1016/j.ajog.2016.03.003. 本文引用 [1]

[28]	Rosenthal AN, Fraser LSM, Philpott S, et al. Evidence of stage shift in women diagnosed with ovarian cancer during phase Ⅱ of the United Kingdom Familial Ovarian Cancer Screening Study[J]. J Clin Oncol, 2017, 35(13):1411-1420. DOI:10.1200/JCO.2016.69.9330. 本文引用 [2]

[29]	Philpott S, Raikou M, Manchanda R, et al. The avoiding late diagnosis of ovarian cancer (ALDO) project;a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2[J]. J Med Genet, 2023, 60(5):440-449. DOI:10.1136/jmg-2022-108741. 本文引用 [2]

[30]	Peshkin BN, Isaacs C. Genetic testing and management of individuals at risk of hereditary breast and ovarian cancer syndromes[EB/OL]. (2024-10-31)[2024-11-20] https://www.uptodate.com/contents/753. https://www.uptodate.com/contents/753 本文引用 [1]

[31]

Peshkin BN, Isaacs C. Overview of hereditary breast and ovarian cancer syndromes[EB/OL]. (2024-01-08)[2024-11-20] https://www.uptodate.com/contents/overview-of-hereditary-breast-and-ovarian-cancer-syndromes. https://www.uptodate.com/contents/overview-of-hereditary-breast-and-ovarian-cancer-syndromes 本文引用 [3]

[32]	Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast,ovarian,and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers[J]. JAMA, 2017, 317(23):2402-2416.DOI:10.1001/jama.2017.7112. 本文引用 [1]

[33]	Mavaddat N, Peock S, Frost D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers:results from prospective analysis of EMBRACE[J]. J Natl Cancer Inst, 2013, 105(11):812-822. DOI:10.1093/jnci/djt095. 本文引用 [1]

[34]	Chen J, Bae E, Zhang L, et al. Penetrance of breast and ovarian cancer in women who carry a BRCA1/2 mutation and do not use risk reducing salpingo-oophorectomy:an updated meta-analysis[J]. JNCI Cancer Spectr, 2020, 4(4):pkaa029. DOI:10.1093/jncics/pkaa029. 本文引用 [1]

[35]	Li S, Silvestri V, Leslie G, et al. Cancer risks associated with BRCA1 and BRCA2 pathogenic variants[J]. J Clin Oncol, 2022, 40(14):1529-1541.DOI:10.1200/JCO.21.02112. 本文引用 [1]

[36]	Mersch J, Jackson MA, Park M, et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian[J]. Cancer, 2015, 121(2):269-275. DOI:10.1002/cncr.29041. 本文引用 [2]

[37]	Segev Y, Iqbal J, Lubinski J, et al. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations:an international prospective cohort study[J]. Gynecol Oncol, 2013, 130(1):127-131. DOI:10.1016/j.ygyno.2013.03.027. 本文引用 [1]

[38]	Pennington KP, Walsh T, Lee M, et al. BRCA1,TP53,and CHEK2 germline mutations in uterine serous carcinoma[J]. Cancer, 2013, 119(2):332-338. DOI:10.1002/cncr.27720. 本文引用 [1]

[39]	Boland CR, Goel A. Microsatellite instability in colorectal cancer[J]. Gastroenterology, 2010, 138(6):2073-2087.e3. DOI:10.1053/j.gastro.2009.12.064. 本文引用 [1]

[40]	Walsh MD, Buchanan DD, Cummings MC, et al. Lynch syndrome-associated breast cancers:clinicopathologic characteristics of a case series from the colon cancer family registry[J]. Clin Cancer Res, 2010, 16(7):2214-2224. DOI:10.1158/1078-0432.CCR-09-3058. 本文引用 [1]

[41]

Hall MJ, Neumann MC. Lynch syndrome (hereditary nonpolyposis colorectal cancer): clinical manifestations and diagnosis[EB/OL]. (2024-07-31)[2024-11-20] https://www.uptodate.com/contents/zh-Hans/lynch-syndrome-hereditary-nonpolyposis-colorectal-cancer-clinical-manifestations-and-diagnosis. https://www.uptodate.com/contents/zh-Hans/lynch-syndrome-hereditary-nonpolyposis-colorectal-cancer-clinical-manifestations-and-diagnosis 本文引用 [1]

[42]	laum N, Crosbie EJ, Woodward ER, et al. MSH2 is the very young onset ovarian cancer predisposition gene,not BRCA1[J]. J Med Genet, 2023, 60(6):576-577. DOI:10.1136/jmg-2022-109055. 本文引用 [1]

[43]	Auranen A, Joutsiniemi T. A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families[J]. Acta Obstet Gynecol Scand, 2011, 90(5):437-444. DOI:10.1111/j.1600-0412.2011.01091.x. 本文引用 [1]

[44]	Chen LM, Yang KY, Little SE, et al. Gynecologic cancer prevention in Lynch syndrome/hereditary nonpolyposis colorectal cancer families[J]. Obstet Gynecol, 2007, 110(1):18-25. DOI:10.1097/01.AOG.0000267500.27329.85. 本文引用 [1]

[45]	Malkin D. Li-fraumeni syndrome[J]. Genes Cancer, 2011, 2(4):475-484. DOI:10.1177/1947601911413466. 本文引用 [1]

[46]	Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian,fallopian tube,and peritoneal carcinoma identified by massively parallel sequencing[J]. Proc Natl Acad Sci U S A, 2011, 108(44):18032-18037. DOI:10.1073/pnas.1115052108. 本文引用 [1]

[47]	Lu HM, Li S, Black MH, et al. Association of breast and ovarian cancers with predisposition genes identified by large-scale sequencing[J]. JAMA Oncol, 2019, 5(1):51-57. DOI:10.1001/jamaoncol.2018.2956. 本文引用 [2]

[48]	Pilarski R, Burt R, Kohlman W, et al. Cowden syndrome and the PTEN hamartoma tumor syndrome:systematic review and revised diagnostic criteria[J]. J Natl Cancer Inst, 2013, 105(21):1607-1616. DOI:10.1093/jnci/djt277. 本文引用 [1]

[49]	Cummings S, Alfonso A, Hughes E, et al. Cancer risk associated with PTEN pathogenic variants identified using multigene hereditary cancer panel testing[J]. JCO Precis Oncol, 2023,7:e2200415. DOI:10.1200/PO.22.00415. 本文引用 [1]

[50]	Hemminki A, Markie D, Tomlinson I, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome[J]. Nature, 1998, 391(6663):184-187. DOI:10.1038/34432. 本文引用 [1]

[51]	Beggs AD, Latchford AR, Vasen HF, et al. Peutz-Jeghers syndrome:a systematic review and recommendations for management[J]. Gut, 2010, 59(7):975-986. DOI:10.1136/gut.2009.198499. 本文引用 [1]

[52]	Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome[J]. Clin Cancer Res, 2006, 12(10):3209-3215. DOI:10.1158/1078-0432.CCR-06-0083. 本文引用 [2]

[53]	Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome[J]. Gastroenterology, 2000, 119(6):1447-1453. DOI:10.1053/gast.2000.20228. 本文引用 [1]

[54]	Wang Z, Wang Z, Wang Y, et al. High risk and early onset of cancer in Chinese patients with Peutz-Jeghers syndrome[J]. Front Oncol, 2022,12:900516. DOI: 10.3389/fonc.2022.900516. 本文引用 [4]

[55]	Chen HY, Jin XW, Li BR, et al. Cancer risk in patients with Peutz-Jeghers syndrome:A retrospective cohort study of 336 cases[J]. Tumour Biol, 2017, 39(6):1010428317705131. DOI:10.1177/1010428317705131. 本文引用 [1]

[56]	Bridge WL, Vandenberg CJ, Franklin RJ, et al. The BRIP1 helicase functions independently of BRCA1 in the fanconi anemia pathway for DNA crosslink repair[J]. Nat Genet, 2005, 37(9):953-957. DOI:10.1038/ng1627. 本文引用 [1]

[57]	Ramus SJ, Song H, Dicks E, et al. Germline mutations in the BRIP1,BARD1,PALB2,and NBN genes in women with ovarian cancer[J]. J Natl Cancer Inst, 2015, 107(11):djv214. DOI:10.1093/jnci/djv214. 本文引用 [1]

[58]	Tung N, Domchek SM, Stadler Z, et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations[J]. Nat Rev Clin Oncol, 2016, 13(9):581-588. DOI:10.1038/nrclinonc.2016.90. 本文引用 [1]

[59]	Tischkowitz M, Balmaña J, Foulkes WD, et al. Management of individuals with germline variants in PALB2:a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)[J]. Genet Med, 2021, 23(8):1416-1423. DOI:10.1038/s41436-021-01151-8. 本文引用 [1]

[60]	Pylkäs K, Erkko H, Nikkilä J, et al. Analysis of large deletions in BRCA1,BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families[J]. BMC Cancer, 2008,8:146. DOI:10.1186/1471-2407-8-146. 本文引用 [1]

[61]	Reid S, Schindler D, Hanenberg H, et al. Biallelic mutations in PALB2 cause fanconi anemia subtype FA-N and predispose to childhood cancer[J]. Nat Genet, 2007, 39(2):162-164. DOI:10.1038/ng1947. 本文引用 [1]

[62]	Yang X, Leslie G, Doroszuk A, et al. Cancer risks associated with germline PALB2 pathogenic variants:an international study of 524 families[J]. J Clin Oncol, 2020, 38(7):674-685. DOI:10.1200/JCO.19.01907. 本文引用 [1]

[63]	Song H, Dicks EM, Tyrer J, et al. Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer[J]. J Med Genet, 2021, 58(5):305-313. DOI:10.1136/jmedgenet-2019-106739. 本文引用 [1]

[64]	Yang X, Song H, Leslie G, et al. Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D[J]. J Natl Cancer Inst, 2020, 112(12):1242-1250. DOI:10.1093/jnci/djaa030. 本文引用 [2]

[65]	Song H, Dicks E, Ramus SJ, et al. Contribution of germline mutations in the RAD51B,RAD51C,and RAD51D genes to ovarian cancer in the population[J]. J Clin Oncol, 2015, 33(26):2901-2907. DOI:10.1200/JCO.2015.61.2408. 本文引用 [2]

[66]	Mansfield SA, Pilarski R, Agnese DM. ATM mutations for surgeons[J]. Fam Cancer, 2017, 16(3):407-410. DOI:10.1007/s10689-016-9959-4. 本文引用 [1]

[67]	Paglia LL, Laugé A, Weber J, et al. ATM germline mutations in women with familial breast cancer and a relative with haematological malignancy[J]. Breast Cancer Res Treat, 2010,119:443. DOI:10.1007/s10549-009-0396-z. 本文引用 [1]

[68]	Zeng C, Bastarache LA, Tao R, et al. Association of pathogenic variants in hereditary cancer genes with multiple diseases[J]. JAMA Oncol, 2022, 8(6):835-844. DOI:10.1001/jamaoncol.2022.0373. 本文引用 [1]

[69]	Giri VN, Knudsen KE, Kelly WK, et al. Implementation of germline testing for prostate cancer:Philadelphia Prostate Cancer Consensus Conference 2019[J]. J Clin Oncol, 2020, 38(24):2798-2811. DOI:10.1200/JCO.20.00046. 本文引用 [1]

[70]	中华医学会妇科肿瘤学分会. 中国妇科肿瘤临床实践指南2024版[M]// 马丁,梁志清. 卵巢癌. 北京: 科学技术文献出版社, 2024. 本文引用 [2]

[71]	Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set[J]. Ann Oncol, 2021, 32(9):1167-1177. DOI:10.1016/j.annonc.2021.05.806. 本文引用 [2]

[72]	Widschwendter M, Zikan M, Wahl B, et al. The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer[J]. Genome Med, 2017, 9(1):116. DOI:10.1186/s13073-017-0500-7. 本文引用 [3]

[73]	Gao Y, Liu CJ, Li HY, et al. Platelet RNA enables accurate detection of ovarian cancer:an intercontinental,biomarker identification study[J]. Protein Cell, 2023, 14(6):579-590. DOI:10.1093/procel/pwac056. 本文引用 [3]

[74]	Yang F, Tang J, Zhao Z, et al. Circulating tumor DNA:a noninvasive biomarker for tracking ovarian cancer[J]. Reprod Biol Endocrinol, 2021, 19(1):178. DOI:10.1186/s12958-021-00860-8. 本文引用 [2]

[75]	Yokoi A, Matsuzaki J, Yamamoto Y, et al. Integrated extracellular microRNA profiling for ovarian cancer screening[J]. Nat Commun, 2018, 9(1):4319. DOI:10.1038/s41467-018-06434-4. 本文引用 [2]

[76]	Zuckerbrot-Schuldenfrei M, Aviel-Ronen S, Zilberberg A, et al. Ovarian cancer is detectable from peripheral blood using machine learning over T-cell receptor repertoires[J]. Brief Bioinform, 2024, 25(2):bbae075. DOI:10.1093/bib/bbae075. 本文引用 [2]

[77]	Wang P, Ma J, Li W, et al. Profiling the metabolome of uterine fluid for early detection of ovarian cancer[J]. Cell Rep Med, 2023, 4(6):101061. DOI:10.1016/j.xcrm.2023.101061. 本文引用 [2]

[78]	Chen S, Tang Y, Li Y, et al. Design and application of prodrug fluorescent probes for the detection of ovarian cancer cells and release of anticancer drug[J]. Biosens Bioelectron, 2023,236:115401. DOI:10.1016/j.bios.2023.115401. 本文引用 [2]

[79]	Xiang H, Xiao Y, Li F, et al. Development and validation of an interpretable model integrating multimodal information for improving ovarian cancer diagnosis[J]. Nat Commun, 2024, 15(1):2681. DOI:10.1038/s41467-024-46700-2. 本文引用 [2]

[80]	Barrett JE, Jones A, Evans I, et al. The DNA methylome of cervical cells can predict the presence of ovarian cancer[J]. Nat Commun, 2022, 13(1):448. DOI:10.1038/s41467-021-26615-y. 本文引用 [2]